Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

bixdo Builds Its IFA 2026 Beauty Tech Showcase Around Everyday Routines

September 5, 2026

Content creators drop the ball

September 5, 2026

The weird and wonderful headphones of CanJam 2026

September 5, 2026

Changan Officially Launches SDA Pilot to Deliver Safer, Smoother and Stress-Free Intelligent Driving

September 5, 2026

EarthCam Commemorates 25th Anniversary of 9/11 with Historic Time-Lapse and Documentary

September 5, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » BNP and NTproBNP Market Research Report 2026: Increasing Demand for Early Cardiac Diagnosis and Prognostic Testing Strengthens Adoption – Trends, Opportunities, and Forecasts 2021-2031
Press Release

BNP and NTproBNP Market Research Report 2026: Increasing Demand for Early Cardiac Diagnosis and Prognostic Testing Strengthens Adoption – Trends, Opportunities, and Forecasts 2021-2031

By News RoomFebruary 26, 20263 Mins Read
BNP and NTproBNP Market Research Report 2026: Increasing Demand for Early Cardiac Diagnosis and Prognostic Testing Strengthens Adoption – Trends, Opportunities, and Forecasts 2021-2031
Share
Facebook Twitter LinkedIn Pinterest Email

Dublin, Feb. 26, 2026 (GLOBE NEWSWIRE) — The “BNP and NTproBNP Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030” has been added to ResearchAndMarkets.com’s offering.

The Global BNP and NTproBNP Market, valued at USD 1.92 Billion in 2024, is projected to experience a CAGR of 7.15% to reach USD 2.91 Billion by 2030

Brain Natriuretic Peptide (BNP) and N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) are cardiac biomarkers secreted by cardiomyocytes in response to ventricular stretch or pressure overload, serving as critical diagnostic indicators for heart failure and other cardiovascular conditions. The market for these diagnostic assays is substantially driven by the increasing global incidence of cardiovascular diseases and the expanding geriatric population, which is particularly susceptible to cardiac ailments.

Key Market Drivers

The growth of the Global BNP and NTproBNP Market is significantly influenced by the escalating prevalence of cardiovascular diseases and the expanding geriatric population increasingly susceptible to heart conditions. The rising incidence of cardiovascular diseases necessitates widespread diagnostic and prognostic tools like BNP and NTproBNP assays for early detection and disease management.

According to the World Health Organization, in 2022, an estimated 19.8 million people died from cardiovascular diseases, highlighting the profound global health burden these conditions impose. Concurrently, the increasing longevity of populations worldwide contributes to a higher prevalence of age-related cardiac ailments. This demographic shift directly fuels demand for cardiac biomarkers.

Key Market Challenges

The inherent limited specificity of Brain Natriuretic Peptide and N-terminal pro-B-type Natriuretic Peptide tests significantly impedes market expansion. Elevated levels of these biomarkers can arise from various non-cardiac conditions, such as renal failure and pulmonary embolism, potentially leading to false-positive diagnoses and complicating clinical interpretation. This lack of singular diagnostic clarity diminishes confidence in the tests as standalone indicators for heart failure.

Key Market Trends

The expanding integration of point-of-care (PoC) testing represents a significant trend in the global BNP and NTproBNP market by decentralizing diagnostic capabilities and enabling rapid clinical decisions. PoC devices provide immediate results, crucial for managing acute cardiac events and enhancing patient throughput in emergency settings.

This trend reflects a broader move towards more accessible and efficient diagnostic pathways. For instance, the American College of Cardiology in a journal scan from August 2024, highlighted a 2-hour strategy for point-of-care high-sensitivity cardiac troponin I testing in suspected acute myocardial infarction, underscoring the drive for expedited cardiac biomarker assessment.

Key Attributes:

Report Attribute Details
No. of Pages 185
Forecast Period 2024 – 2030
Estimated Market Value (USD) in 2024 $1.92 Billion
Forecasted Market Value (USD) by 2030 $2.91 Billion
Compound Annual Growth Rate 7.1%
Regions Covered Global


Report Scope

Key Market Players Profiled:

  • Specim, Spectral Imaging Ltd
  • Gentian Diagnostics ASA
  • Siemens AG
  • PerkinElmer Inc
  • Biomerieux SA
  • Quidel Corporation
  • Bio-Rad Laboratories, Inc.
  • F. Hoffman-La Roche Ltd
  • BHR Pharmaceuticals Ltd.
  • Xiamen Biotime Biotechnology Co., Ltd.

By Type:

  • Brain Natriuretic Peptide
  • NT-proBNP (N-terminal Pro-B-Type Natriuretic Peptide)

By Location of Testing:

  • Point Of Care Testing
  • Laboratory Testing

By Application:

  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome (ACS)
  • Others

By Region:

  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

For more information about this report visit https://www.researchandmarkets.com/r/prnuol

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


            
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

bixdo Builds Its IFA 2026 Beauty Tech Showcase Around Everyday Routines

Changan Officially Launches SDA Pilot to Deliver Safer, Smoother and Stress-Free Intelligent Driving

EarthCam Commemorates 25th Anniversary of 9/11 with Historic Time-Lapse and Documentary

Tivaro Anniversary Sale: 15% Off EW5004 and EW8001 Pro Electric Wheelchairs

iFLYTEK Showcases AI Across Work, Home and Marketing at IFA 2026

Proscenic and Ultenic to Showcase Whole-Home Smart Cleaning Portfolio at IFA 2026

AnchorLess Announces Online Spanish NIF Assistance for Foreign Entrepreneurs and Investors

XRP Market Volatility Drives Demand for AI Automated Trading as MoneySimpler Expands Access to Quantitative Strategies

LUXEED Hosts Dedicated Brand Engagement Session with Chery International Middle East Dealer Delegation

Editors Picks

Content creators drop the ball

September 5, 2026

The weird and wonderful headphones of CanJam 2026

September 5, 2026

Changan Officially Launches SDA Pilot to Deliver Safer, Smoother and Stress-Free Intelligent Driving

September 5, 2026

EarthCam Commemorates 25th Anniversary of 9/11 with Historic Time-Lapse and Documentary

September 5, 2026

Latest News

OpenAI admits to German wiki ‘incident’

September 5, 2026

Tivaro Anniversary Sale: 15% Off EW5004 and EW8001 Pro Electric Wheelchairs

September 5, 2026

iFLYTEK Showcases AI Across Work, Home and Marketing at IFA 2026

September 5, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version